.png){kind=icon}
.png){kind=icon}
Return
Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents
.png){kind=icon}
OA
AI
M
L
S
D
Y
C
A
DOI：10.1016/j.jamda.2026.106365.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral for COVID-19. Although effective, its use is complicated by clinically important potential drug-drug interactions (DDIs). Long-term care facility (LTCF) residents are especially vulnerable to both COVID-19 and the adverse effects of potential DDIs because of advanced age, multimorbidity, and polypharmacy. The objective of this study was to quantify the prevalence and duration of potential DDIs among US LTCF residents administered nirmatrelvir/ritonavir.
Keywords:
COVID-19
drug-drug interaction
long-term care facility residents
nirmatrelvir/ritonavir
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.8
Papers:
5.7K
Citations:
1.7W
Organization
Cited Papers